Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is headquartered in Cremorne, Australia.

Rhinomed Limited

Bird Healthcare is an Australian owned company with over 30 years experience in developing, manufacturing and selling medical innovations, primarily in the respiratory and sleep medicine markets.

Bird Healthcare

B Medical Systems is a global manufacturer and distributor of medical-grade devices, specializing in cold chain solutions for the safe storage and transport of vaccines, blood components, and laboratory specimens.

B Medical Systems

Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and commercializing treatments for patients with genetic, metabolic, and life-threatening disorders in Australia, Europe, the United States, Switzerland, and internationally. Its lead drug candidate is SCENESSE, a systemic photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which provoke prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited t to treat EPP patients with SCENESSE under a named patient program in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.

Clinuvel Pharmaceuticals Limited

Rhinomed is a global medical device company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery.

Metric
Company Name	Rhinomed Limited	Bird Healthcare	B Medical Systems	Clinuvel Pharmaceuticals Limited
Symbol	RNO			CUV
MSH ID	GLOBAL:RHINOMED	COM:BIRDHEALTHCARE	COM:BMEDICALSYSTEMS	COM:CLINUVEL
Market	STOCKS	PRIVATE	PRIVATE	STOCKS
Sector	Healthcare	Healthcare & Health Services	Healthcare & Health Services	Healthcare
Industry	Medical - Devices	Medical Devices	Medical Equipment and Supplies	Biotechnology
Country	AU	AU	LU	AU
Stage
Employee Count		11		16
Website	rhinomed.global	birdhealthcare.com	bmedicalsystems.com	clinuvel.com
LinkedIn
Founders

Metric
Market Cap	7.33M	481.89M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue	5.82M	56.34M
Revenue (LTM)
Revenue (NTM)
Gross Profit	3.97M	49.90M
EBITDA	-2.90M	35.96M
Operating Income	-3.35M	35.23M
Net Income	-3.37M	22.77M
EPS	-0.01	0.45
Diluted EPS	-0.01	0.44
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.33	0.76
Operating Profit Margin	-0.48	0.53
EBITDA Margin	-0.50	0.64
Net Profit Margin	-0.95	0.41
Return on Equity	5.28	0.19
Return on Assets		0.15
Return on Capital Employed		0.22

GLOBAL:RHINOMED

Rhinomed

Last Close

0.04

14/02 04:41

Market Cap

11.47M

Beta: -

Volume Today

217.26K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.73	26.62
P/B Ratio	-1.22	4.95
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	1.00	10.72
EV Multiple	-2.89	22.57

Metric
Days Sales Outstanding	70.62	103.53
Days Payables Outstanding	336.54	135.48
Days Inventory Outstanding		188.05
Operating Cycle		297.33
Cash Conversion Cycle		255.83
Asset Turnover		0.38

Metric
Operating Cash Flow	-4.59M	23.68M
Free Cash Flow	-4.65M	20.11M
Cash Flow to Debt		118.80
Operating Cash Flow/Sales	-0.94	0.52
Free Cash Flow Yield	-0.91	0.05

Metric
Cash & Equivalents	1.27M	117.49M
Accounts Receivable	380.94K	-2.57M
Inventory	793.44K	6.79M
Goodwill	999.99K
Debt to Capitalization		0.01
Debt to Assets	1.91	0.01
Current Ratio	0.27	7.44
Quick Ratio		8.39

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.11
R&D to Revenue	0.15	0.02
SG&A to Revenue	0.16	0.02